• 1. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 2. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylmethylamines

Recent Advances in the Study of 1-(1-Benzylpyrrolidin-3-yl)ethan-1-one (CAS: 87088-73-1) in Chemical Biology and Pharmaceutical Research

The compound 1-(1-benzylpyrrolidin-3-yl)ethan-1-one (CAS: 87088-73-1) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug discovery and development. This briefing synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and therapeutic potential. The compound's unique structural features, including the benzylpyrrolidine moiety and the ethanone group, make it a promising candidate for further investigation.

Recent studies have explored the synthetic pathways for 1-(1-benzylpyrrolidin-3-yl)ethan-1-one, highlighting its efficient production through multi-step organic reactions. Researchers have optimized the synthesis to improve yield and purity, which is critical for its application in high-throughput screening and medicinal chemistry. The compound's structural analogs have also been investigated, revealing insights into structure-activity relationships (SAR) that could guide future drug design efforts.

In terms of biological activity, preliminary in vitro and in vivo studies suggest that 1-(1-benzylpyrrolidin-3-yl)ethan-1-one exhibits notable interactions with central nervous system (CNS) targets. Specifically, it has shown affinity for neurotransmitter receptors, including dopamine and serotonin receptors, which are implicated in various neurological and psychiatric disorders. These findings open new avenues for the development of novel therapeutics for conditions such as depression, anxiety, and Parkinson's disease.

Further pharmacological evaluations have demonstrated the compound's potential as a lead molecule in the treatment of neurodegenerative diseases. Its ability to cross the blood-brain barrier (BBB) and modulate neurochemical pathways has been a focal point of recent research. Additionally, its low toxicity profile in preclinical models underscores its suitability for further development.

Despite these promising results, challenges remain in the clinical translation of 1-(1-benzylpyrrolidin-3-yl)ethan-1-one. Issues such as metabolic stability, pharmacokinetics, and potential off-target effects need to be addressed through rigorous preclinical and clinical studies. Collaborative efforts between academia and industry are essential to overcome these hurdles and advance the compound toward therapeutic application.

In conclusion, 1-(1-benzylpyrrolidin-3-yl)ethan-1-one (CAS: 87088-73-1) represents a compelling area of research in chemical biology and pharmaceutical sciences. Its unique properties and promising biological activities position it as a valuable candidate for future drug development. Continued research and innovation will be crucial to unlocking its full therapeutic potential and addressing the unmet medical needs in CNS disorders.

• 23504-21-4(4-Piperidinone, 5-methyl-3-(2-oxopropyl)-1-(phenylmethyl)-)
• 344256-56-0(4-Piperidinone, 1-(phenylmethyl)-3-propyl-)
• 373604-07-0(4-Piperidinone, 3-(1-methylethyl)-1-(phenylmethyl)-)
• 500170-22-9(Cycloheptanone, 2-[[bis(phenylmethyl)amino]methyl]-, (2S)-)
• 101046-32-6(cis-2-benzyl-1,3,3a,5,6,6a-hexahydrocyclopenta[c]pyrrol-4-one)
• 178425-08-6(3-Heptanone, 1-[bis(phenylmethyl)amino]-2,6-dimethyl-, (2R)-)
• 178425-07-5(3-Heptanone, 1-[bis(phenylmethyl)amino]-2-methyl-, (2R)-)
• 390410-25-0(3-Hexanone, 1-[bis(phenylmethyl)amino]-2-methyl-)
• 185692-51-7(2-Benzyl-hexahydro-cyclopentacpyrrol-4-one)
• 879687-90-8(2-benzyl-octahydro-1H-isoindol-4-one)